The HMG-CoA reductase inhibitor pravastatin stimulates insulin secretion through organic anion transporter polypeptides

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 3, 2010, Pages 274-282

  Abe, Michiaki ^a   Toyohara, Takafumi ^a   Ishii, Akiko ^b   Suzuki, Takehiro ^a   Noguchi, Naoya ^c   Akiyama, Yasutoshi ^a   Shiwaku, Hiromi O ^a   Nakagomi Hagihara, Rie ^d   Zheng, Guodong ^a   Shibata, Eisuke ^a   Souma, Tomokazu ^a   Shindo, Tomohiko ^a   Shima, Hirohito ^a   Takeuchi, Yoichi ^a   Mishima, Eikan ^a   Tanemoto, Masayuki ^a   Terasaki, Tetsuya ^a   Onogawa, Tohru ^c   Unno, Michiaki ^c   Ito, Sadayoshi ^a   Takasawa, Shin ^e   Abe, Takaaki ^a,c   more..

^a TOHOKU UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d DAIICHI SANKYO CO   (Japan)

^e NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adipose; Diabetes; Disease; Endobiotics; Hmg coa reductase inhibitors; Insulin; Islet; Oatp; Organ; Slc transporters; Slco (slc21); Xenobiotics

Indexed keywords

BROMSULFOPHTHALEIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; PRAVASTATIN; RIFAMPICIN; ADIPONECTIN; ADIPOQ PROTEIN, MOUSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INSULIN;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; ENDOCRINE CELL; EXPERIMENTAL RAT; GENE EXPRESSION; GENE LOCATION; GLYCEMIC CONTROL; INSULIN RELEASE; INSULINOMA; MALE; NONHUMAN; PANCREAS; RAT; AGONISTS; ANIMAL; ANIMAL MODEL; BLOOD; CYTOLOGY; DIABETES MELLITUS; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; INBRED MOUSE STRAIN; METABOLISM; MOUSE; PANCREAS ISLET; SECRETION (PROCESS); TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ADIPONECTIN; ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DIABETES MELLITUS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; IMMUNOHISTOCHEMISTRY; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED STRAINS; MODELS, ANIMAL; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PANCREAS; PRAVASTATIN; RATS; RIFAMPIN; SULFOBROMOPHTHALEIN;

EID: 77954272440     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.25.274     Document Type: Article

References (31)

1. Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W., McKillop, J. H. and Packard, C. J.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med., 333: 1301-1307 (1995).
2. Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., Packard, C. J., Shepherd, J. and Gaw, A.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation, 103: 357-362 (2001).
3. Komai, T., Shigehara, E., Tokui, T., Koga, T., Ishigami, M., Kuroiwa, C. and Horiuchi, S.: Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem. Pharmacol., 43: 667-670 (1992).
4. Abe, T., Kakyo, M., Sakagami, H., Tokui, T., Nishio, T., Tanemoto, M., Nomura, H., Hebert, S. C., Matsuno, S., Kondo, H. and Yawo, H.: Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. J. Biol. Chem., 273: 22395-22401 (1998).
5. Tokui, T., Nakai, D., Nakagomi, R., Yawo, H., Abe, T. and Sugiyama, Y.: Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm. Res., 16: 904-908 (1999).
6. Abe, T., Kakyo, M., Tokui, T., Nakagomi, R., Nishio, T., Nakai, D., Nomura, H., Unno, M., Suzuki, M., Naitoh, T., Matsuno, S. and Yawo, H.: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem., 274: 17159-17163 (1999).
7. Nakai, D., Nakagomi, R., Furuta, Y., Tokui, T., Abe, T., Ikeda, T. and Nishimura, K.: Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J. Pharmacol. Exp. Ther., 297: 861-867 (2001).
8. Thelen, K. M., Rentsch, K. M., Gutteck, U., Heverin, M., Olin, M., Andersson, U., von Eckardstein, A., Bjorkhem, I. and Lutjohann, D.: Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther., 316: 1146-1152 (2006).
9. Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P. A. and Wollheim, C. B.: Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology, 130: 167-178 (1992).
10. Kakyo, M., Sakagami, H., Nishio, T., Nakai, D., Nakagomi, R., Tokui, T., Naitoh, T., Matsuno, S., Abe, T. and Yawo, H.: Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide 2 (oatp2). FEBS Lett., 445: 343-346 (1999).
11. Santini, E., Fallahi, P., Ferrari, S. M., Masoni, A., Antonelli, A. and Ferrannini, E.: Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells. Diabetes, 53 Suppl 3: S79-83 (2004).
12. van Montfoort, J. E., Stieger, B., Meijer, D. K., Weinmann, H. J., Meier, P. J. and Fattinger, K. E.: Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J. Pharmacol. Exp. Ther., 290: 153-157 (1999).
13. Okamoto, H.: Regulation of proinsulin synthesis in pancreatic islets and a new aspect to insulin-dependent diabetes. Mol. Cell Biochem., 37: 43-61 (1981).
14. Kato, I., Yamamoto, Y., Fujimura, M., Noguchi, N., Takasawa, S. and Okamoto, H.: CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, [Ca2+]i, and insulin secretion. J. Biol. Chem., 274: 1869-1872 (1999).
15. Belmonte, S. A., Lopez, C. I., Roggero, C. M., De Blas, G. A., Tomes, C. N. and Mayorga, L. S.: Cholesterol content regulates acrosomal exocytosis by enhancing Rab3A plasma membrane association. Dev. Biol., 285: 393-408 (2005).
16. Unger, R. H.: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes, 44: 863-870 (1995).
17. Tsujita, Y., Kuroda, M., Shimada, Y., Tanzawa, K., Arai, M., Kaneko, I., Tanaka, M., Masuda, H., Tarumi, C., Watanabe, Y. and Fujii, S.: CS-514, a competitive inhibitor of 3-hydroxy-3- methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta, 877: 50-60 (1986).
18. Sakamoto, K., Sakamoto, T. and Ogawa, H.: The effect of 6 months of treatment with pravastatin on serum adiponectin concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study. Clin. Ther., 28: 1012-1021 (2006).
19. Shoji, T., Nishizawa, Y., Toyokawa, A., Kawagishi, T., Okuno, Y. and Morii, H.: Decreased albuminuria by pravastatin in hyperlipidemic diabetics. Nephron, 59: 664-665 (1991).
20. Ishida, H., Takizawa, M., Ozawa, S., Nakamichi, Y., Yamaguchi, S., Katsuta, H., Tanaka, T., Maruyama, M., Katahira, H., Yoshimoto, K., Itagaki, E. and Nagamatsu, S.: Pioglitazone improves insulin secretory capacity and prevents the loss of betacell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress. Metabolism, 53: 488-494 (2004).
21. Brunham, L. R., Kruit, J. K., Pape, T. D., Timmins, J. M., Reuwer, A. Q., Vasanji, Z., Marsh, B. J., Rodrigues, B., Johnson, J. D, Parks, J. S., Verchere, C. B. and Hayden, M. R.: Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med., 13: 340-347 (2007).
22. Calabro, P. and Yeh, E. T.: The pleiotropic effects of statins. Curr. Opin. Cardiol., 20: 541-546 (2005).
23. Jacquemin, E., Hagenbuch, B., Stieger, B., Wolkoff, A. W. and Meier, P. J.: Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc. Natl. Acad. Sci. USA, 91: 133-137 (1994).
24. B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W. P. and Kirchgessner, T. G.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liverspecific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem., 274: 37161-37168 (1999).
25. Yamazaki, M., Suzuki, H., Hanano, M., Tokui, T., Komai, T. and Sugiyama, Y.: Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am. J. Physiol., 264: G36-44 (1993).
26. A. K., van Thiel, G. C., Huisman, R. H., Moshage, H., Yap, S. H. and Cohen, L. H.: Different effects of 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim. Biophys. Acta, 1254: 105-111 (1995).
27. Brunham, L. R., Kruit, J. K., Verchere, C. B. and Hayden, M. R.: Cholesterol in islet dysfunction and type 2 diabetes. J. Clin. Invest., 118: 403-408 (2008).
28. Ishikawa, M., Okajima, F., Inoue, N., Motomura, K., Kato, T., Takahashi, A., Oikawa, S., Yamada, N. and Shimano, H.: Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J. Atheroscler. Thromb., 13: 329-335 (2006).
29. Guclu, F., Ozmen, B., Hekimsoy, Z. and Kirmaz, C.: Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed. Pharmacother., 58: 614-618 (2004).
30. Takagi, T., Matsuda, M., Abe, M., Kobayashi, H., Fukuhara, A., Komuro, R., Kihara, S., Caslake, M. J., McMahon, A., Shepherd, J., Funahashi, T. and Shimomura, I.: Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis, 196: 114-121 (2008).
31. Albert, M. A., Danielson, E., Rifai, N. and Ridker, P. M.: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/ CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, 286: 64-70 (2001).